Company Profile
Description
HBM Partners is a globally active and independent healthcare‐focused investment advisor with over USD 2.4 billion in assets under management. HBM focuses on development‐stage, growth and buy‐out financings of private companies as well as investments in public companies. Core target sectors are pharma & biotech, medical devices, diagnostics and related areas. HBM Partners advises HBM Healthcare Investments, HBM BioCapital I & II and further public-equity funds.
Number of employees in Switzerland
25
Capital under Management
USD 2.4bn
Fund Names
HBM Healthcare Investments, HBM BioCapital I+II, public-equity funds
Number of Portfolio Companies
60-100
Examples of Portfolio Companies
Advanced Accelerator Applications (exited), Armo BioSciences (exited), Cathay Industrial Biotech, ConnectRN, Dren Bio, Ellipse Technologies (exited), Harmony BioSciences, Neurelis, Numab Therapeutics, SpringWorks Therapeutics, Upstream Bio
Year of Establishment
2001
Investments
Type of Firm
All
Investment Stages
All
Industrial Sectors
Biotechnology, Medical - Life Sciences - Health Related
Geographical Focus
Asia, India, United States of America, Western Europe
Type of Financing
Equity Financing
Investment preferences
Currency
-
Size of Investment
USD 5-40m
Funds available to invest
CHF 600m
Minimum investment considered
CHF 5m
Maximum investment considered
CHF 50m
